Related references
Note: Only part of the references are listed.Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
David M. Ross et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib
Cesarina Giallongo et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Patient perceptions of treatment-free remission in chronic myeloid leukemia
Lucia A. Villemagne Sanchez et al.
LEUKEMIA & LYMPHOMA (2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele et al.
LANCET ONCOLOGY (2018)
Subsets of CD4+, CD8+, and CD25hi Lymphocytes Are in General Not Influenced by Isolation and Long-Term Cryopreservation
Andrea Tompa et al.
JOURNAL OF IMMUNOLOGY (2018)
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
David M. Ross et al.
LEUKEMIA (2018)
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy
Delphine Rea et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
M. Ilander et al.
LEUKEMIA (2017)
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
Simone Claudiani et al.
HAEMATOLOGICA (2017)
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
Delphine Rea et al.
HAEMATOLOGICA (2017)
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
C. Schuetz et al.
LEUKEMIA (2017)
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
Simone Claudiani et al.
HAEMATOLOGICA (2017)
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
Delphine Rea et al.
HAEMATOLOGICA (2017)
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Amy Hughes et al.
FRONTIERS IN IMMUNOLOGY (2017)
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
Amy Hughes et al.
BLOOD (2017)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Jason D. Fontenot et al.
JOURNAL OF IMMUNOLOGY (2017)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function
Heinrich Schlums et al.
IMMUNITY (2015)
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
Jun Imagawa et al.
LANCET HAEMATOLOGY (2015)
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Stacie B. Dusetzina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Immunology and Immunotherapy of Chronic Myeloid Leukemia
Mette Ilander et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ
Christian Schuerch et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection
Joachim Koch et al.
TRENDS IN IMMUNOLOGY (2013)
Increased natural killer cells and decreased CD3+CD8+CD62L+T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib
Kazuma Ohyashiki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples
Athanasios Kotsakis et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Regularization Paths for Generalized Linear Models via Coordinate Descent
Jerome Friedman et al.
JOURNAL OF STATISTICAL SOFTWARE (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data
Vivian G. Oehler et al.
BLOOD (2009)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
Building Predictive Models in R Using the caret Package
Max Kuhn
JOURNAL OF STATISTICAL SOFTWARE (2008)
Cutting edge: Lectin-like transcript 1 is a ligand for the CD161 receptor
H Aldemir et al.
JOURNAL OF IMMUNOLOGY (2005)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2003)
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
JJ Molldrem et al.
NATURE MEDICINE (2000)
Share Paper
